Velan Capital Investment Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Velan Capital Investment Management’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-548,841	Closed	-$2.54M	–	34
2022 Q3	$2.54M	Sell	548,841 -51,159	-9%	-$301K	2.52%	11
2022 Q2	$3.04M	Hold	600,000	–	–	3.08%	9
2022 Q1	$4.28M	Hold	600,000	–	–	3.97%	10
2021 Q4	$5.85M	Buy	+600,000	New	+$5.33M	4.54%	7

Other funds holding STLN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Velan Capital Investment Management's STLN Position: Q4 2022 in Review

Velan Capital Investment Management sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2022, closing a stake of 548,841 shares — an estimated $2.54M sold.

Velan Capital Investment Management first reported a position in STLN in Q4 2021 and held it in 4 quarters. The position peaked at $5.85M in Q4 2021. 41 funds tracked by Wall St. Rank hold STLN as of Q4 2022.

Velan Capital Investment Management reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Velan Capital Investment Management sold 548,841 Starling Oncology Institute, Inc. Common Stock shares in Q4 2022, an estimated $2.54M.
Velan Capital Investment Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
Velan Capital Investment Management's Starling Oncology Institute, Inc. Common Stock position peaked at $5.85M in Q4 2021.
41 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2022.

Based on Velan Capital Investment Management's 13F filing for Q4 2022, filed 13 Feb 2023.